BigCapital beta

Moscow Exchange · PRMD · IFRS

Promomed: revenue, profit and cash flow

In 2025, Promomed had revenue of ₽37.6B and a net profit of ₽7.04B, according to its consolidated IFRS statements. Here: 4 years of annual reports since 2022, each linked to the original document.

Revenue, 2025

₽37.6B+75.2%

change against 2024

Net profit
₽7.04B
attributable to shareholders · 18.7% of revenue
Earnings per share, 2025
₽35.26
Operating cash flow
₽267M
Capital expenditure
₽1.87B
Free cash flow
−₽1.6B
operating cash flow minus capital expenditure
Net debt
₽24.2B
borrowings minus cash; leases not included
Dividends paid
₽403M
Total assets
₽71B
Equity
₽26.3B

Where the money goes

Of every ₽100 of revenue in 2025, Promomed spent ₽32.3 on the cost of its products and services and ₽31.1 on running the business (₽30.2 of it on selling and administration); ₽6.9 went to income tax, ₽10.9 went to interest and other items, and ₽18.7 was left as net profit.

2025 · rubles · share of revenue
In 2025AmountOf revenue
Revenue₽37.6B100.0%
Cost of revenue−₽12.2B32.3%
Gross profit₽25.4B67.7%
Sales & admin−₽11.4B30.2%
Other operating−₽339M0.9%
Operating profit₽13.7B36.5%
Income tax−₽2.59B6.9%
Interest and other, net−₽4.1B10.9%
Net profit₽7.04B18.7%

Revenue and net profit

Revenue went from ₽13.5B in 2022 to ₽37.6B in 2025.

RevenueNet profit
Rubles, as reported (IFRS); years without a report are left out.

Earnings per share

Basic earnings per share went from ₽19.88 in 2022 to ₽35.26 in 2025.

Years · rubles per share, basic, adjusted for share splits

Operating cash flow, capex and free cash flow

Free cash flow (operating cash flow minus capital expenditure) was −₽1.6B in 2025, −4.3% of revenue. Negative in 2022–2025.

Operating cash flowCapital expenditureFree cash flow
Rubles, as reported (IFRS); years without a report are left out.

What it owns and who paid for it

At the end of 2025, Promomed had ₽71B of assets, ₽4.21B of it in cash. They were paid for by ₽28.4B of borrowings, ₽16.2B of other liabilities and ₽26.3B of shareholders' equity: equity is 37.1% of the assets.

End of 2025 · rubles · share of assets · sizes across years on a square-root scale

Net debt

Net debt (borrowings minus cash) was ₽24.2B at the end of 2025. That is 1.6 times its EBITDA of ₽15.1B (operating profit plus depreciation and amortisation).

Net debt
Rubles, as reported (IFRS); years without a report are left out.

Dividends paid

In 2025, Promomed paid ₽403M in dividends, 6% of its net profit for the year.

Dividends paid
Rubles, as reported (IFRS); years without a report are left out.

Promomed: annual figures

YearRevenueOperating profitNet profitBasic EPSOperating cash flowCapital expenditureFree cash flowNet debtDividends paidTotal assetsEquity
2025₽37.6B₽13.7B₽7.04B₽35.26₽267M₽1.87B−₽1.6B₽24.2B₽403M₽71B₽26.3B
2024₽21.4B₽6.9B₽2.86B₽13.94₽93M₽2.65B−₽2.56B₽16.4B₽346M₽53.1B₽19.3B
2023₽15.8B₽5.6B₽2.99B₽14.95−₽1.19B₽2.9B−₽4.09B₽15.6B₽174M₽34.8B₽13B
2022*₽13.5B₽5.35B₽3.98B₽19.88₽2.96B₽4.63B−₽1.67B₽9.03B₽601M₽25.9B₽10.3B

* Taken from the comparative column of the next year's report: the year's own report was not available to us.

Original reports

Every figure on this page comes from the company's own annual statements. The documents, by year:

How to read these numbers

Source: annual financial statements published by Promomed (links to the original documents above). Figures read from the documents by BigCapital.

For information only, not investment advice.

Language

EnglishBahasa IndonesiaDeutschEspañolFrançaisItalianoNederlandsPolskiPortuguêsTürkçeРусскийУкраїнська日本語한국어简体中文